Tuesday, August 30, 2011

BWI: New study finds Cervical Cancer as the Largest Killer in Indian Women and Lung Cancer in Males in India

Press release from Business Wire India
Source: AceProbe
Tuesday, August 30, 2011 06:31 PM IST (01:01 PM GMT)
Editors: General: Consumer interest; Business: Business services, Healthcare, biotechnology & pharmaceutical; Technology; Healthcare
New study finds Cervical Cancer as the Largest Killer in Indian Women and Lung Cancer in Males in India
Cervical Cancer surpasses the incidence of Breast Cancer in Indian Women

New Delhi, Delhi, India, Tuesday, August 30, 2011 -- (Business Wire India) -- Recent disclosure by WHO, Cervical Cancer has emerged as the largest killer, surpassing breast cancer. Cervical cancer also emerged as a cancer having larger existence among the figures for both men and women put together.

An estimated 73,000 new cases of Cervical Cancer are reported in Indian Women and the incidence is reported to about 1,32,000 cases annually, that happen to be about 30% of the total about 4,70,000 new cases of cervical cancer reported annually, reports WHO. These deaths owing to the cervical cancer cause are largely preventable and are likely to significantly reduce the cost burden of disease, delivering a health society.

A recent study that shows that " Mass-ARRAY spectrometry is more sensitive than existing technologies for type specific detection of high risk oncogenic HPV ( Human Papilloma Virus) genotypes in cervical cancer" is the success story behind the effective collaborative outcome between a leading cancer hospital in Kolkata, Industry and international public health foundation that confirms and establishes the claim, to be able to open up better healthcare through cutting edge technology and expertise on home ground, comparable to those of many developed countries and leading hospitals to include Memorial Sloan Kettering Cancer Center, Dana Faber and Rosewell Park in the United Sates to name a few.

Commenting on the study, Dr. Partha Basu, Head, Department of Gynecologic Oncology at CNCI hospital Kolkata states, " The study confirms, the MassARRAY technology and the current panel has the advantage of both sensitivity and providing information about the high risk genotype of the HPV causing cervical cancer."

Technical expert and Co-Author and in the study, Dr. Puneet Chandna, Managing Director of AceProbe Technologies (I) Pvt. Ltd. said, "This breakthrough research could not have been achieved without a collaborative mode under the Public Private Partnership scheme of the Govt. Of India and we are sure to unravel many such potential clinical outcomes with the intent of getting these to a common man to access these healthcare breakthrough investigations on the home land in India.

Dr. Chandna and his company is working across the country with many leading centers on similar feasibilities in the area of Oncology, Cardiology, Infectious diseases and nutritional aspects for life style diseases.

Worldwide regulator bodies now choose to employ such sensitive methods in parallel to their national vaccination programs that could accurately and in an efficient manner be able to detect multiple high risk types of the virus HPV (Human Papilloma Virus) being the major cause of the deadly cancer of cervix. Even Indian regulatory bodies under its various schemes continue to explore and implement projects for effective and definitive outcome in the area of concern.

The effective propagation and collaborative outcomes of research have now started to take shape and time is not far when masses, could access the benefits of such Personalised Genetics Prognostic Solutions for disease susceptibility, therapy response, for an informed choice of treatment that works for them, to lead a quality life ahead.

ABOUT AceProbe:

AceProbe has evolved with a team of Biotech professionals and operates in the niche are of genomic that enable its partners to efficiently design and perform experiments, monitor progress, receive and interpret results, and making the adoption of technology in a trivial manner. By partnering with AceProbe, scientists can rapidly discover complex connections between genetic profiles, disease risk and therapeutic response, with ease.

Their comprehensive Technology Platform and Services allow access to a multitude of clinical and research data, key analysis modules for both genotype and expression information, and database archiving and processing capabilities. Flexible platform and custom service features for a medium-density, ultra-high-throughput, customizable format make all its offerings unique with unmatched credentials and allows researchers to stratify patient populations prior to conducting clinical trials

Manoj Sharma, Fact Communications, +91 9811135420


If you wish to change your Business Wire India selection please click on this link http://www.businesswireindia.com/media/news.asp and use your personal username and password to login.

Submit your press release at http://www.businesswireindia.com

No comments:

Post a Comment